Tag: Wipro GE Healthcare

News

Wipro GE Healthcare Announces Investment of Over INR8000 Crores in Manufacturing Output & Local R&D Over Next 5 Years

Mar 28, 2024 by Praveen 0 Comments #BENGALURU, #Chairman, #Wipro GE Healthcare, #zim Premji

Bengaluru ,March,2024: Wipro GE Healthcare, a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, today announced an investment of over INR8000 Crores in manufacturing output & local R&D over next 5 years. Poised for exponential growth, MedTech, the Sunrise Sector is thriving with the hospital industry in India, accounting for 80% of the total healthcare market and witnessing strong investor demand locally and globally. This strategic investment bolsters Wipro GE Healthcare’s local manufacturing footprint to address the growing domestic and international market and will build supply chain resiliency for the organization. As a part of this investment, the Wipro GE Healthcare ‘Made in India’ PET CT Discovery IQ will be exported to 15 countries. Additionally, the ‘Made in India’ Revolution Aspire CT, Revolution ACT and MR breast coils will be manufactured ‘In India for the World’.

Wipro GE Healthcare Announces Investment of Over INR8000 Crores in Manufacturing Output & Local R&D Over Next 5 Years

India is among the top 20 global markets for medical devices in the world.  Wipro GE Healthcare is among the first MedTech companies to ‘Make in India – for India and the world’ over past three decades, investing upwards of over $4Billion in R&D and manufacturing output in India since inception. Over the decades, the organization has fostered a strong local supplier ecosystem of MedTech component manufacturing – covering capabilities like plastics, EMS, machining, castings, 3D printing – contributing $1M supplier Labor hours. The investment will include creation of additional 400,000 labor hours.

Azim Premji, Chairman, Wipro GE Healthcare, Chairman, Wipro Enterprises and Chairman Azim Premji Foundation, said, “India is riding the resurgent growth in the healthcare industry and rapidly expanding MedTech sector. With ‘Make in India’, we are witnessing an exponential expansion of manufacturing footprint in the country, strengthening India’s capability as the MedTech hub of the world. Wipro GE Healthcare has been committed to this localization journey for over three decades and this strategic investment is testament to our vision for this sector.”

Peter J. Arduini, President and CEO, GE HealthCare said, “India is a high potential, high priority market for GE HealthCare globally. In fact, we are among the first MedTech companies to ‘Make in India – for India and the World’. We will continue to invest in expanding India’s domestic capabilities and its global footprint in MedTech manufacturing and R&D. Today’s announcement is aligned with our strategic vision to deliver precision innovation globally and accelerate India’s position as ‘MedTech innovation and manufacturing hub for India and for world markets.”

Chaitanya Sarawate, Managing Director, Wipro GE Healthcare and President & CEO, GE HealthCare South Asia said, “Innovating in India and Making in India – for India and for the World, has always been a priority for us, evident in our trajectory and investments over past three decades. We have fostered a strong innovation track record, a local supplier ecosystem and built a portfolio of world class products in India, for India and the world. As a local partner we are bullish about India’s potential and its journey to be ‘Atmanirbhar’ and a key cog in the resilient global supply chain. As India envisions to be among top five global manufacturing hubs in terms of value and technology for Medical Devices in the coming years, we are committed to the national healthcare agenda.”

Currently, the organization has four manufacturing plants in Bengaluru. All four manufacturing plants are export plants – the latest one established in March 2022 with an investment of a little over INR100 crore under the Indian government’s PLI Scheme.

GE HealthCare is among the first healthcare companies to start an R&D center in India over three decades back. The Healthcare Technology Center India (HTCI) is GE HealthCare’s largest R&D center outside of the USA, situated in John F. Welch Technology Centre (JFWTC), Bengaluru. The organization also has collaborations with leading academic institutions in the country to further research. In January 2024, GE HealthCare signed an MoU with Indian Institute of Science (IISc) to advance MedTech innovation from India – for India and the world.

News

IISc Signs MoU with Wipro GE Healthcare to Advance MedTech Innovation

Jan 27, 2024 by Sujata Muguda 0 Comments #Chaitanya Sarawate, #Govindan Rangarajan, #Indian Institute of Science (IISc), #Wipro GE Healthcare, #World Health Organisation

Bengaluru 27th Jan, 2024: Wipro GE Healthcare, a leading global medical technology, diagnostics, and digital solutions innovator today signed a Memorandum of Understanding (MoU) with the Indian Institute of Science (IISc), India’s premier research institution, for a pioneering alliance to advance healthcare innovation, research, and technology development in India. This collaboration aims to take a comprehensive approach in solving the care gap by addressing the full lifecycle that includes co-developing solutions, validating the technologies, and manufacturing them locally to bring them to the market. With the impending commencement of the Bagchi-Parthasarathy Hospital & IISc Medical School, this strategic collaboration will enable translation of technologies from bench to bedside.

According to World Health Organisation Report 2018, “Globally, Non-Communicable Diseases (NCDs) accounted for 71% of total deaths. In India, NCDs were estimated to account for 63% of all deaths, and cancer was one of the leading causes (9%).”[1] This industry-academia collaboration aims to advance indigenous innovation and manufacturing of MedTech products that meets the needs of both global and local patients suffering from NCDs including cancer, cardiology, and neurology in line with the agenda of ‘Atmanirbhar Bharat’.

The collaboration will entail co-development initiatives in the areas of basic and applied science, systems engineering, product & software development, consultancy, publications, academic studies, internships, fellowships, and training. IISc and GE HealthCare will constitute a joint working committee, comprising representatives from both sides, for research around product and solution development.

IISc Signs MoU with Wipro GE Healthcare to Advance MedTech Innovation from India - for India and the World (1)

Govindan Rangarajan, Director, Indian Institute of Science (IISc), said, “We see a tremendous need for innovative R&D that can improve outcomes in patients with NCD. The collaboration will emphasise combining science and engineering with translational & clinical research to epitomize “bench-to-bedside” innovation. GE HealthCare is the right partner for us in this initiative, given their leadership and strong footprint in India for R&D and manufacturing. We are confident that together, we can accelerate India’s position as a global force for healthcare for the world.”

Chaitanya Sarawate, Managing Director, Wipro GE Healthcare and President & CEO, GE HealthCare South Asia, said, “India today is at an inflection point, with a potential to become the hub for the world. IISc is a premier educational institute engaged in technical education, basic and applied research, innovation, entrepreneurship, and industrial consultancy and GE HealthCare is a world leader in MedTech with strategic R&D and manufacturing footprint in India. This is a strategic collaboration that combines the strengths, capabilities, and local infrastructure of both entities. Our aim together is to invest in technologies of the future that can revolutionize the care paradigm – with more precise, connected, and compassionate care to patients in India and worldwide.”

The collaboration aligns with the Indian Government’s emphasis on fostering local Research and Development (R&D) and Manufacturing in the MedTech sector, necessitating Public-Private Partnership (PPP) models to further drive technology development. Collaborative efforts by both the entities will be deployed for product development and clinical research, improving indigenization of manufacturing and academic activities to strengthen the healthcare ecosystem.